benzofuran-5-yldifluoroacetic acid ethyl ester | 943541-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: benzofuran-5-yldifluoroacetic acid ethyl ester
• 英文别名: Benzofuran-5-yl-difluoroacetic acid ethyl ester；ethyl 2-(1-benzofuran-5-yl)-2,2-difluoroacetate
• CAS: 943541-56-8
• 化学式: C₁₂H₁₀F₂O₃
• 分子量: 240.206
• InChiKey: KTQLNOCUQDLAFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzofuran-5-yldifluoroacetic acid ethyl ester 在 肼 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以99%的产率得到benzofuran-5-yldifluoroacetic acid hydrazide
  参考文献：
  名称：

  WO2007/75567

  摘要：

  公开号：
• 作为产物：
  描述：

  benzofuran-5-yloxo-acetic acid ethyl ester 在 二甲氨基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以79%的产率得到benzofuran-5-yldifluoroacetic acid ethyl ester
  参考文献：
  名称：

  WO2007/75567

  摘要：

  公开号：

文献信息

• TRIAZOLOPYRIDAZINES AS KINASE MODULATORS
  申请人：Lu Tianbao

  公开号：US20090098181A1

  公开（公告）日：2009-04-16

  The invention is directed to triazolopyridazine compounds of Formula I: where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这种化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这种化合物来减少或抑制细胞或受体中c-Met的激酶活性，调节细胞或受体中c-Met的表达，并使用这种化合物预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• Triazolopyridazine compounds
  申请人：Janssen Pharmaceutica N.V.

  公开号：US08173654B2

  公开（公告）日：2012-05-08

  The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，使用这些化合物来减少或抑制细胞或主体中c-Met的激酶活性，并调节细胞或主体中c-Met的表达，以及使用这些化合物预防或治疗主体中的细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• Triazolopyridazines as kinase modulators
  申请人：Janssen Pharmaceutica N.V.

  公开号：US08030305B2

  公开（公告）日：2011-10-04

  The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，以及使用这样的化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这样的化合物来减少或抑制细胞或主体中c-Met的激酶活性，并调节细胞或主体中c-Met的表达，以及使用这样的化合物预防或治疗主体中的细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP1966214B1

  公开（公告）日：2016-11-02
• US8030305B2
  申请人：——

  公开号：US8030305B2

  公开（公告）日：2011-10-04